Salveen Richter

The American Epilepsy Society (AES) annual meeting is scheduled to be held between December 2 and 6, during which GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) will present on its lead anti-epilepsy drug Epidiolex, providing data from the first two positive Phase 3 studies. What To Expect The...

Goldman Sachs’ Salveen Richter believes that bluebird bio Inc’s (NASDAQ: BLUE) second generation (Gen 2) LentiGlobin gene therapy is three times more potent than Gen 1, which is good news for rare blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (...

Following the release of top-line data from Kite Pharma Inc (NASDAQ: KITE)'s ZUMA-1 trial of its lead CAR T drug KTE-C19 at the European Society of Clinical Oncology, Goldman Sachs said the focus now shifts toward commercial outlook. The drug is being tested for relapsed/refractory lymphoma....

The lead candidate of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), Epidiolex, has yielded positive results in three Phase III studies in two severe orphan epilepsies. “We anticipate a solid launch trajectory,” Goldman Sachs’ Salveen Richter said in a report. He initiated...

Seattle Genetics, Inc. (NASDAQ: SGEN) received a ratings bump from Goldman Sachs to Neutral from Sell after the brokerage revised its Adcetris U.S. sales estimates in 1L Hodgkin's lymphoma (HL) "to reflect greater market penetration per physician diligence." "We model 40 percent penetration (vs. 19...

bluebird bio Inc (NASDAQ: BLUE) shares are up 19 percent since the company announced its Gen2 LentiGlobin had entered the clinic on September 8, although Goldman Sachs’ Salveen Richter believes there are catalysts that could drive further upside in 2016/17 and beyond. Richter maintained a...

Goldman Sachs’ Salveen Richter believes that are no major catalysts for Atara Biotherapeutics Inc (NASDAQ: ATRA) ahead of the EBV-CTL pivotal data, which is expected in late-2017 or later. Richter downgraded the rating on the company from Neutral to Sell, while lowering the price target...

Pfizer Inc. (NYSE: PFE) finalized a deal to acquire Medivation Inc (NASDAQ: MDVN) for $14 billion Monday morning. Goldman Sachs’ Jami Rubin has a 12-month price target of $37 for Pfizer. Rubin stated that the acquisition would be consistent with Pfizer’s “stated interest in...

Expressing optimism regarding the 2H prospects of bluebird bio Inc (NASDAQ: BLUE), Goldman Sachs’ Salveen Richter maintained a Buy rating on the company, with a price target of $135. The analyst believes Bluebird Bio is “entering a key value-inflection point.” Bluebird Bio is...

Goldman Sachs remains bullish on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) despite the company withdrawing its EU application for Kyndrisa in Duchenne muscular dystrophy (DMD). The move follows the May 23-26 CHMP meeting which indicated a negative opinion was forthcoming. Saying that the...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) rose 10 percent in the pre-market trading after FDA approved its drug Ocaliva to treat a rare liver disease. Ocaliva (obeticholic acid) is approved for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis...